Aadi Bioscience, Inc. v. EOC Pharma (Hong Kong) Limited

CourtDistrict Court, S.D. New York
DecidedJuly 21, 2025
Docket1:24-cv-09412
StatusUnknown

This text of Aadi Bioscience, Inc. v. EOC Pharma (Hong Kong) Limited (Aadi Bioscience, Inc. v. EOC Pharma (Hong Kong) Limited) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Aadi Bioscience, Inc. v. EOC Pharma (Hong Kong) Limited, (S.D.N.Y. 2025).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK ─────────────────────────────────── AADI BIOSCIENCE, INC., Petitioner, 24-cv-9412 (JGK)

- against - MEMORANDUM OPINION AND ORDER EOC PHARMA (HONG KONG) LTD.,

Respondent. ─────────────────────────────────── JOHN G. KOELTL, District Judge: The petitioner, Aadi Bioscience, Inc. (“Aadi”) filed this petition (the “Petition” or “Pet.”) to confirm an arbitration award (the “Award”) pursuant to the Convention on the Recognition and Enforcement of Foreign Arbitral Awards (the “New York Convention”), 21 U.S.T. 2517, and Chapter 2 of the Federal Arbitration Act (“FAA”), 9 U.S.C. § 201, et seq., against the respondent, EOC Pharma (Hong Kong) Limited (“EOC”). For the following reasons, the Petition is granted. I. The following undisputed facts are taken from the Petition, the Award, and the parties’ “License Agreement.” On June 27, 2022, EOC, an oncology drug company based in Hong Kong, commenced an arbitration against Aadi, a biopharmaceutical company based in California, alleging that Aadi breached the parties’ License Agreement, which governed EOC’s importation and commercial distribution of a novel drug developed by Aadi. See Pet. ¶¶ 5–8, ECF No. 1; Bassin Decl., Ex. B. (“Award”) at 8, ECF No. 6-2. EOC sought damages for Aadi’s alleged breach of the License Agreement. See Award at 8. The License Agreement contained an arbitration clause

providing for binding arbitration, administered by the International Chamber of Commerce (“ICC”) in New York. See Bassin Decl., Ex. A (“License Agreement”) § 13.02, ECF No. 6-1. After briefing and an evidentiary hearing, the ICC Tribunal issued an Award, concluding that Aadi did not breach the License Agreement and was not liable to EOC. See Pet. ¶¶ 8–12; see also Award at 62. The Tribunal also ordered each party to bear its own costs and fees. Pet. ¶ 12. On December 10, 2024, Aadi brought this action against EOC seeking to confirm the Award. See ECF No. 1. EOC failed to respond to the Petition. On June 5, 2025, Aadi filed an order to show cause as to why the Petition should not be considered unopposed and EOC again failed to

respond. See ECF Nos. 21, 23. Accordingly, the Petition will be considered unopposed. II. The Court has subject matter jurisdiction over the Petition pursuant to the New York Convention. In implementing the New York Convention, section 203 of Chapter 2 of the FAA provides that “[a]n action or proceeding falling under the [New York] Convention shall be deemed to arise under the laws and treaties of the United States.” 9 U.S.C. § 203. A four-part test governs whether an action “fall[s] under” the New York Convention. That test requires that “(1) there must be a written agreement; (2) it must provide for arbitration in the territory of a signatory

of the convention; (3) the subject matter must be commercial; and (4) it cannot be entirely domestic in scope.” Smith/Enron Cogeneration Ltd. P’ship v. Smith Cogeneration Int’l, Inc., 198 F.3d 88, 92 (2d Cir. 1999). In this case, all four requirements have been satisfied. The License Agreement is a written agreement, providing for arbitration in New York, and governs a commercial matter. Further, because EOC is a Hong Kong corporation with its principal place of business in Hong Kong, the arbitration involves “parties domiciled or having their principal place of business outside the enforcing jurisdiction,” Bergesen v. Joseph Muller Corp., 710 F.2d 928, 932 (2d Cir. 1983), and is therefore

non-domestic, see Yusuf Ahmed Alghanim & Sons v. Toys “R” Us, Inc., 126 F.3d 15, 18-19 (2d Cir. 1997).1 Moreover, Aadi is a Delaware corporation with its principal place of business in Pacific Palisades, California. Pet. ¶ 5. EOC is a Hong Kong corporation with its principal place of business in Hong Kong. Id. ¶ 6. Because the amount in

1 Unless otherwise noted, this Memorandum Opinion and Order omits all alterations, citations, footnotes, and internal quotation marks in quoted text. controversy exceeds $75,000, see Award at 32, this Court also has diversity jurisdiction over the action. See 28 U.S.C. § 1332(a)(2).

III. Where—as in this case—the respondent fails to respond to the petition, “the Court must do more than simply issue a default judgment in favor of the petitioner.” AAK USA, Inc. v. Integrity Ingredients Corp., No. 25-cv-1727, 2025 WL 1547640, at *1 (S.D.N.Y. May 29, 2025). Instead, “because a motion to confirm or vacate an arbitration award is generally accompanied by a record,” “the petition and accompanying record should be treated as akin to a motion for summary judgment based on the movant’s submissions.” Id. (quoting D.H. Blair & Co. v. Gottdiener, 462 F.3d 95, 109 (2d Cir. 2006)). The standard for granting summary judgment is well

established. The Court “shall grant summary judgment if the movant shows that there is no genuine dispute as to any material fact and the movant is entitled to judgment as a matter of law.” Fed. R. Civ. P. 56(a); see Celotex Corp. v. Catrett, 477 U.S. 317, 322–23 (1986). The substantive law governing the case will identify those facts that are material, and “[o]nly disputes over facts that might affect the outcome of the suit under the governing law will properly preclude the entry of summary judgment.” Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 248 (1986). “Even when a motion for summary judgment is unopposed, the district court is not relieved of its duty to decide whether the movant is entitled to judgment as a matter of

law.” Vt. Teddy Bear Co. v. 1-800 Beargram Co., 373 F.3d 241, 242 (2d Cir. 2004). Rather, “[i]f the evidence submitted in support of the summary judgment motion does not meet the movant’s burden of production, then summary judgment must be denied even if no opposing evidentiary matter is presented.” Id. at 244. IV. “The confirmation of an arbitration award is a summary proceeding that merely makes what is already a final arbitration award a judgment of the court.” Florasynth, Inc. v. Pickholz, 750 F.2d 171, 176 (2d Cir. 1984). “To avoid undermining the twin goals of arbitration, namely, settling disputes efficiently and

avoiding long and expensive litigation, arbitral awards are subject to very limited review.” Zurich Am. Ins. Co. v. Team Tankers A.S., 811 F.3d 584, 588 (2d Cir. 2016). In cases arising under the New York Convention, as this case does, “[t]he court shall confirm the award unless it finds one of the grounds for refusal or deferral of recognition or enforcement of the award specified in [Article V of the New York] Convention.” 9 U.S.C. § 207. Article V provides that a court need not confirm an arbitral award where: (a) The parties to the agreement . . . were . . .

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Aadi Bioscience, Inc. v. EOC Pharma (Hong Kong) Limited, Counsel Stack Legal Research, https://law.counselstack.com/opinion/aadi-bioscience-inc-v-eoc-pharma-hong-kong-limited-nysd-2025.